Core - Pilot Program

核心 - 试点计划

基本信息

批准号：
10380649
负责人：
SUBHASH C. PANDEY
金额：
$ 12.95万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10380649
关键词：
Advisory Committees Alcohol consumption Alcohol withdrawal syndrome Alcoholism Alcohols Amygdaloid structure Animal Model Anxiety Area Attenuated Autopsy Basic Science Behavioral Biological Markers Blood Cells Brain Brain Diseases Brain Injuries Cells Chronic Clinical Investigator Clinical Research Clinical Trials Committee Members Cutaneous T-cell lymphoma DNA Methylation DNA Modification Process Data Dependence Electronic Mail Epigenetic Process Eukaryotic Initiation Factors FDA approved Funding Funding Mechanisms Future Gene Expression Profile Genes Genomics Histone Deacetylase Histone Deacetylase Inhibitor Leadership Mental Depression Mission Modeling Modification Molecular Motivation Neurosciences Pathogenesis Pilot Projects Play Post-Traumatic Stress Disorders Prefrontal Cortex Procedures Process Program Reviews Prokaryotic Initiation Factor-3 Publications RNA RNA analysis RNA methylation RNA-Binding Proteins Reader Regulation Research Research Personnel Research Project Grants Risk Role Testing Tissue-Specific Gene Expression Traumatic Brain Injury United States National Institutes of Health Vorinostat Withdrawal Work alcohol abuse therapy alcohol comorbidity alcohol exposure alcohol research alcohol use disorder anxiety-like behavior behavioral phenotyping career comorbidity epigenetic marker epigenome epigenomics epitranscriptome epitranscriptomics histone modification innovation member novel operation prevent problem drinker programs transcriptome sequencing transcriptomics

项目摘要

Project Summary: The objective of pilot project core of the P50 application for “Center for Alcohol Research in Epigenetics (CARE)” is to serve as a platform to bring new research directions in alcohol research and attract new investigators to alcohol research field. The overall hypothesis of the CARE is that chronic alcohol exposure and withdrawal changes the epigenome to produce differential gene expression patterns that mechanistically alter brain function during the pathogenesis of alcohol use disorder. We have included two exciting and relevant pilot projects, epigenetic biomarkers in AUD and the epitranscriptome’s role in AUD. A second set of pilot projects will also be announced and then selected for the 3rd and 5th years of CARE funding to cover several important research areas which includes epigenetic basis of post-traumatic stress disorder (PTSD) and tramautic brain injury (TBI) comorbid with AUD. Studies clearly suggest that HDAC inhibitors are able to attenuate alcohol consumption in several animal models of alcoholism. Vorinostat (SAHA) is FDA-approved for the treatment of cutaneous T-cell lymphoma, therefore we propose to conduct an initial clinical study of SAHA in AUD as one of the future pilot projects. Another area that will be explored is single cell epigenomics in AUD. The administrative core of the CARE will provide leadership, overall management, and oversight of current and future pilot projects. The Specific Aims of the pilot project component are: 1) To manage the operation, progress, and completion of current and future pilot projects during CARE funding. 2) To announce new pilot projects and manage the review process by the members of Program Advisory Committee of the CARE. New pilot projects will attract new investigators and interesting research areas to the alcohol research field. These pilot projects will furthermore strengthen the epigenetic theme of CARE and allow these investigators to apply for NIH funding mechanisms to become full-fledged alcohol researchers, thus fulfilling the objectives of the Pilot Project Core.

项目概要： “表观遗传学酒精研究中心（CARE）”P50应用试点项目核心的目标旨在作为一个平台，为酒精研究带来新的研究方向，并吸引新的研究人员酒精研究领域的总体假设是慢性酒精暴露和戒断。改变表观基因组以产生差异基因表达模式，从而机械地改变大脑我们纳入了两个令人兴奋且相关的试点。项目、AUD 中的表观遗传生物标志物以及 AUD 中表观转录组的作用第二组试点项目。还将宣布并选择 CARE 资助的第三年和第五年，以涵盖几个重要的项目研究领域包括创伤后应激障碍（PTSD）和创伤性脑的表观遗传学基础研究清楚地表明，HDAC 抑制剂能够减弱酒精的作用。伏立诺他 (SAHA) 已被 FDA 批准用于治疗多种酒精中毒动物模型。皮肤 T 细胞淋巴瘤，因此我们建议在 AUD 中进行 SAHA 的初步临床研究，作为其中之一未来将探索的另一个领域是 AUD 的单细胞表观基因组学。 CARE 的核心将为当前和未来的试点项目提供领导、全面管理和监督。试点项目部分的具体目标是： 1) 管理运行、进度和完成 CARE 资助期间当前和未来的试点项目 2) 宣布新的试点项目并进行管理。 CARE 项目咨询委员会成员将进行审查。这些试点项目将吸引新的研究人员和有趣的研究领域进入酒精研究领域。进一步加强 CARE 的表观遗传学主题，并允许这些研究人员申请 NIH 资助成为成熟的酒精研究人员的机制，从而实现试点项目核心的目标。